PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3685/8/22 Sandoz

Sandoz: Omnitrope cool bag exceeded Β£10 limit and withdrawal not communicated proactively (AUTH/3685/8/22)

Sandoz supplied an Omnitrope cool bag costing Β£13.66 (over the Β£10 limit) and later withdrew it without proactive stakeholder communication. Breaches of…

2022
CASE
AUTH/3716/11/22 Ferring Pharmaceuticals

Ferring Pharmaceuticals: failure to fully withdraw Pentasa leavepiece with incorrect prescribing information (AUTH/3716/11/22)

Ferring confirmed withdrawal of Pentasa material with incorrect dosing info, but a hidden website hyperlink kept the leavepiece accessible for ~11 weeks.…

2021
CASE
Tetris Pharma ⭐ Case of the Week

Tetris Pharma: LinkedIn sponsored message for Ogluo reached a non-HCP (public promotion) and lacked required safety/INN elements

A LinkedIn sponsored message promoting Ogluo (glucagon) was received by a non-HCP. The Panel found public promotion plus missing INN at first…

2023
CASE
AUTH/3734/2/23 Valneva

Valneva: pharmacy training webinar video deemed promotional after product mentions (AUTH/3734/2/23)

A pharmacy training webinar hosted on a member site/YouTube became promotional when Valneva’s speaker mentioned products and β€œno competitors”, triggering missing AE…

2023
CASE
AUTH/3796/7/23 AstraZeneca

AstraZeneca breached Clause 3.1 after UK employee β€˜liked’ third-party LinkedIn post about phase 3 datopotamab deruxtecan results (AUTH/3796/7/23)

A UK AstraZeneca employee β€˜liked’ a third-party LinkedIn post about positive phase 3 datopotamab deruxtecan results. The Panel said the β€˜like’ disseminated…

2021
CASE
Novo Nordisk

Novo Nordisk breached ABPI Code after employee reposted Financial Times LinkedIn post mentioning Wegovy and Ozempic

A UK-based Novo Nordisk employee reposted an FT LinkedIn post linking to positive claims about Wegovy and Ozempic. The Panel found disguised…

2023
CASE
AUTH/3774/6/23 AstraZeneca

AstraZeneca: senior UK-based employees’ LinkedIn β€˜likes’ treated as promotional dissemination to the public (AUTH/3774/6/23)

Senior UK-based AstraZeneca employees β€˜liked’ LinkedIn posts about Imfinzi combinations and trial results. The Panel found promotion to the public, pre-authorisation promotion,…

2023
CASE
AUTH/3823/9/23 GlaxoSmithKline ⭐ Case of the Week

AUTH/3823/9/23: GSK LinkedIn β€˜likes’ on US momelotinib approval posts – no breach (Clauses 12.1, 12.10, 26.1)

Complaint alleged GSK staff β€˜likes’ on LinkedIn posts about US FDA approval of momelotinib promoted a POM to the UK public without…

2021
CASE
AstraZeneca

AstraZeneca breached ABPI Code over Trixeo mortality webpage: 46% risk reduction claim and graph presentation

AstraZeneca’s Trixeo HCP website mortality section was ruled misleading: prominent β€œ46% risk reduction” and β€œacross all treatment arms” messaging lacked clear context…

2024
CASE
AUTH/3871/1/24 AbbVie

AbbVie breach for inaccurate SPC presentation on EMC: missing dash in Venclyxto dosing schedule (AUTH/3871/1/24)

AbbVie was found in breach of Clause 5.1 after a Venclyxto SPC on EMC showed β€œDays 1 7” instead of β€œDays 1-7”…

2023
CASE
AUTH/3866/12/23 Merck Serono

Merck Serono: third‑party publisher emails for Bavencio found disguised promotion and too frequent (AUTH/3866/12/23)

Third‑party publisher sent repeated Bavencio promotional emails. Panel found promotion was disguised (sender/subject line and poor prominence of sponsorship) and frequency lacked…

2021
CASE
Evolus

Evolus website: missing trial disclosure, NI prescribing info gaps, and mobile black triangle/generic name failures

PMCPA found multiple breaches on Evolus’ Nuceiva website: no homepage clinical trial signpost, NI prescribing info issues, and mobile display failures (black…

2024
CASE
AUTH/3895/5/24 GlaxoSmithKline ⭐ Case of the Week

GSK breach for patient organisation articles: funding acknowledgement not clear from the outset (AUTH/3895/5/24)

Four patient-facing articles funded by a GSK grant disclosed the funding only at the bottom of each page. PMCPA ruled a narrow…

2015
CASE
Bristol-Myers Squibb Pharmaceuticals

Pfizer and Bristol-Myers Squibb: restaurant speaker meetings and concerns about privacy and hospitality (no breach)

Anonymous complaint about two restaurant-based promotional speaker meetings alleged public could overhear and hospitality was excessive. Panel found complainant did not prove…

2008
CASE
AUTH/2122/5/08 Bayer

AUTH/2122/5/08: Anonymous ex-employee v Bayer Schering Pharma – Nebido advertisement (no breach)

An ex-employee alleged a Nebido BMJ ad implied men would become attractive to younger women (unlicensed). The Panel found the imagery reflected…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training